StockData
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc. (RYTM) stock

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30276% above fair value
$119.04+2.43 (+2.08%)

Close on Nov 18, 2026Market cap $8.20BP/E –Yield –

Rhythm Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Rhythm Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2023 was -$136.20M. For fiscal 2025 it was -$116.63M. The highest annual figure on record is -$6.99M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$116.63M–
FY2024Dec 31, 2024-$113.88M–
FY2023Dec 31, 2023-$136.20M–
FY2022Dec 31, 2022-$173.71M–
FY2021Dec 31, 2021-$146.44M–
FY2020Dec 31, 2020-$122.19M–
FY2019Dec 31, 2019-$126.14M–
FY2018Dec 31, 2018-$62.78M–
FY2017Dec 31, 2017-$29.59M–
FY2016Dec 31, 2016-$24.28M–
FY2015Dec 31, 2015-$6.99M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$29.38M–
Q3 FY2023Sep 30, 2023-$29.25M–
Q2 FY2023Jun 30, 2023-$41.09M–
Q1 FY2023Mar 31, 2023-$36.48M–
Q4 FY2022Dec 31, 2022-$34.00M–
Q3 FY2022Sep 30, 2022-$47.08M–
Q2 FY2022Jun 30, 2022-$38.87M–
Q1 FY2022Mar 31, 2022-$53.76M–
Q4 FY2021Dec 31, 2021-$40.54M–
Q3 FY2021Sep 30, 2021-$40.27M–
Q2 FY2021Jun 30, 2021-$32.09M–
Q1 FY2021Mar 31, 2021-$33.54M–
Q4 FY2020Dec 31, 2020-$29.21M–
Q4 FY2019Dec 31, 2019-$32.22M–
Q3 FY2019Sep 30, 2019-$33.86M–
Q2 FY2019Jun 30, 2019-$27.86M–
Q1 FY2019Mar 31, 2019-$32.19M–
Q4 FY2018Dec 31, 2018-$21.38M–
Q3 FY2018Sep 30, 2018-$17.26M–
Q4 FY2017Dec 31, 2017-$7.94M–
Q4 FY2016Dec 31, 2016-$6.18M–

More Rhythm Pharmaceuticals figures

See a number that looks wrong?